A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn’s Disease

BACKGROUND AND AIMS: Lower-cost biosimilar infliximab may address affordability concerns in the treatment of adults with Crohn’s disease (CD), however, evidence regarding the cost-effectiveness of switching from reference to biosimilar is warranted. The aim of this research was to assess the increme...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Avery, Marshall, John K, Moretti, Myla E, Ungar, Wendy J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898373/
https://www.ncbi.nlm.nih.gov/pubmed/33644677
http://dx.doi.org/10.1093/jcag/gwz045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898373/
https://www.ncbi.nlm.nih.gov/pubmed/33644677
http://dx.doi.org/10.1093/jcag/gwz045

Ejemplares similares